SynthesisThe Cochrane database of systematic reviews2005
Artemether-lumefantrine (six-dose regimen) for treating uncomplicated falciparum malaria.
Synthesis in The Cochrane database of systematic reviews, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it, 66 citations in OpenAlex.
- Artemisinin-based combination therapy for treating uncomplicated malaria.The Cochrane database of systematic reviews · 2009Pooled it
- Artemether-lumefantrine (four-dose regimen) for treating uncomplicated falciparum malaria.The Cochrane database of systematic reviews · 2006Pooled it
- Trial
- Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults.The Journal of antimicrobial chemotherapy · 2012Trial
- Open-label trial with artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria three years after its broad introduction in Jimma Zone, Ethiopia.Malaria journal · 2012Trial
- Adherence to and acceptability of artemether-lumefantrine as first-line anti-malarial treatment: evidence from a rural community in Tanzania.Malaria journal · 2010Trial
- Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children.Malaria journal · 2009Trial
- Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children.Malaria journal · 2008Trial
- Gaps in knowledge and use of artemether-lumefantrine among university students in Southwestern Nigeria: A cross-sectional study.PloS one · 2026Article
- Exploring Subtilisin Inhibition to Discover Antimalarial Drugs: Insights into Medicinal Chemistry and Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Lumefantrine ameliorates DSS-induced colitis by targeting FLI-1 to suppress NF-κB signaling.Frontiers in pharmacology · 2025Article
- Recent advances in malaria drug discovery.Bioorganic & medicinal chemistry letters · 2013Review
- Successful oral therapy for severe falciparum malaria: the World Health Organization criteria revisited.The American journal of tropical medicine and hygiene · 2012Article
- Evidence-based clinical guidelines for immigrants and refugees.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011Article
- Artemether-Lumefantrine Combination Therapy for Treatment of Uncomplicated Malaria: The Potential for Complex Interactions with Antiretroviral Drugs in HIV-Infected Individuals.Malaria research and treatment · 2011Article
- Evidence for perinatal and child health care guidelines in crisis settings: can Cochrane help?BMC public health · 2010Article
- Update on the efficacy, effectiveness and safety of artemether-lumefantrine combination therapy for treatment of uncomplicated malaria.Therapeutics and clinical risk management · 2010Article
- Artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria.Therapeutics and clinical risk management · 2009Article
- Malaria: an update on treatment of adults in non-endemic countries.BMJ (Clinical research ed.) · 2006Review
- Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda.PLoS clinical trials · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe World Health Organization recommends artemether-lumefantrine for treating uncomplicated malaria. We sought evidence of superiority of the six-dose regimen over existing treatment regimens as well as its effectiveness in clinical situations.
objectivesTo evaluate the six-dose regimen of artemether-lumefantrine for treating uncomplicated falciparum malaria. SEARCH STRATEGY: We searched the Cochrane Infectious Diseases Group Specialized Register (April 2005), CENTRAL (The Cochrane Library Issue 1, 2005), MEDLINE (1966 to April 2005), EMBASE (1974 to April 2005), LILACS (1982 to April 2005), conference proceedings, and reference lists of articles. We also contacted experts in malaria research and the pharmaceutical company that manufactures artemether-lumefantrine. SELECTION CRITERIA: Randomized controlled trials comparing six doses of artemether-lumefantrine administered orally with standard treatment regimens (single drug or combination), or supervised with unsupervised treatment, for uncomplicated falciparum malaria. DATA COLLECTION AND ANALYSIS: Two authors independently applied inclusion criteria to potentially relevant trials, assessed trial quality, and extracted data, including adverse events. Total failure by day 28 (day 42 for sulfadoxine-pyrimethamine and day 63 for mefloquine) was the primary outcome. MAIN
resultsNine trials (4547 participants) tested the six-dose regimen. Total failure at day 28 for artemether-lumefantrine was lower when compared with amodiaquine (270 participants, 1 trial), amodiaquine plus sulfadoxine-pyrimethamine (507 participants, 1 trial), but not with chloroquine plus sulfadoxine-pyrimethamine (201 participants, 2 trials). In comparisons with artemisinin derivative combinations, artemether-lumefantrine performed better than amodiaquine plus artesunate (668 participants, 2 trials), worse than mefloquine plus artesunate (270 participants, 4 trials), and no differently to dihydroartemisinin-napthoquine-trimethoprim (89 participants, 1 trial). AUTHORS'
conclusionsThe six-dose regimen of artemether-lumefantrine appears more effective than antimalarial regimens not containing artemisinin derivatives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.